Short Bowel Syndrome Market Is Projected To Reach Worth USD 2.9 Mn By 2025

SAN JOSE, Calif. - Oct. 21, 2019 - PRLog -- According to the latest report published by Credence Research, Inc. the short bowel syndrome market was estimated at US$ 315.1 million in 2016 and is expected to reach US$ 2.901.0 million by 2025, rising to CAGR by 27.5 per cent from 2017 to 2025.

Market Insights

Short bowel syndrome is a complex disease group that arises due to a small and/or large intestine failure. Individuals with short bowel syndrome show poor absorption of nutrients such as milk, fats, carbohydrates, vitamins, minerals and other essential elements contributing to obesity, weight loss. However in some cases, short bowel syndrome can lead to serious, life-threatening and disabling complications. There is no particular cure for this disorder however the surgical removal (resection) of half or more of the small intestine is successful. Short bowel syndrome can lead to Crohn's disease, illness, or small intestine trauma. Such complications make a significant contribution to the development of the market for short bowel syndrome. On the basis of drugs, the market is divided into GLP-2, glutamine, growth hormone and others. GLP-2 currently holds the largest market for drugs in the short bowel syndrome market as it is marketed in the U.S. and Europe under the brand names Gattex and Revestive in Europe and other international markets. Drugs currently hold the status of orphan drugs, and the exclusivity of drugs in the treatment of short bowel syndrome would continue to generate huge revenues during the forecast period.

Browse Full Report Originally Published by Credence Research at https://www.credenceresearch.com/report/short-bowel-syndrome-market

North America held the largest market in the short bowel syndrome market with U.S. being the highest grossing country. The major factor driving the U.S. short bowel syndrome market is the rising prescription of Gattex, which is the only approve drug in the U.S. Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. Europe held the second largest market as in the U.S., approximately 6,000-7,000 SBS patients are dependent on parenteral support with a similar prevalence in Europe. Revestive is the highest grossing drug in the Europe which is marketed by Shire, plc. Moreover, efficient reimbursement scenario in North America and Europe would further drive the market for short bowel syndrome during the forecast period.